33823126|t|Effects of L-dopa on expression of prolactin and synaptotagmin IV in 17-beta-estradiol-induced prolactinomas of ovariectomized hemiparkinsonian rats.
33823126|a|Parkinson's disease (PD) is a long-term degenerative disorder of the central nervous system that mainly affects the motor system. Dopamine precursor levodopa (L-dopa) is used as the first-line treatment for PD. Evidence suggests neuroprotective effects of estrogens in PD. Since both 17b-estradiol (E2) and L-dopa act as regulators of prolactin (PRL) secretion from the pituitary gland, we investigated their effect on the expression of PRL in prolactinomas that developed in ovariectomized hemiparkinsonian rats treated with E2. We also investigated the effect of E2 and L-dopa on the expression of synaptotagmin IV (Syt IV), an immediate early gene whose product is abundant in the pituitary gland and was found to be highly co-expressed with PRL in lactotrophs (>90%). The hemiparkinsonian rat model was obtained by unilateral lesioning of dopaminergic nigrostriatal neurons. Rats received silastic tubing implants with E2 and were treated with L-dopa. Enzyme-linked immunosorbent assay and immunohistochemistry were used to assess the serum concentrations of PRL and E2 and expression of PRL and Syt IV in the tissue of adenohypophysis, respectively. We found that high levels of serum E2 were associated with the upregulation of Syt IV and PRL in PRL-ir cells, while treatment with L-dopa decreased the size of prolactinomas and downregulated Syt IV but had no effect on PRL expression or serum concentrations.
33823126	11	17	L-dopa	Chemical	MESH:D007980
33823126	35	44	prolactin	Gene	24683
33823126	49	65	synaptotagmin IV	Gene	64440
33823126	69	86	17-beta-estradiol	Chemical	MESH:D004958
33823126	95	108	prolactinomas	Disease	MESH:D015175
33823126	127	143	hemiparkinsonian	Disease	
33823126	144	148	rats	Species	10116
33823126	150	169	Parkinson's disease	Disease	MESH:D010300
33823126	171	173	PD	Disease	MESH:D010300
33823126	190	241	degenerative disorder of the central nervous system	Disease	MESH:D019636
33823126	280	288	Dopamine	Chemical	MESH:D004298
33823126	299	307	levodopa	Chemical	MESH:D007980
33823126	309	315	L-dopa	Chemical	MESH:D007980
33823126	357	359	PD	Disease	MESH:D010300
33823126	419	421	PD	Disease	MESH:D010300
33823126	434	447	17b-estradiol	Chemical	-
33823126	449	451	E2	Chemical	MESH:D004958
33823126	457	463	L-dopa	Chemical	MESH:D007980
33823126	485	494	prolactin	Gene	24683
33823126	496	499	PRL	Gene	24683
33823126	587	590	PRL	Gene	24683
33823126	594	607	prolactinomas	Disease	MESH:D015175
33823126	641	657	hemiparkinsonian	Disease	
33823126	658	662	rats	Species	10116
33823126	676	678	E2	Chemical	MESH:D004958
33823126	715	717	E2	Chemical	MESH:D004958
33823126	722	728	L-dopa	Chemical	MESH:D007980
33823126	750	766	synaptotagmin IV	Gene	64440
33823126	768	774	Syt IV	Gene	64440
33823126	895	898	PRL	Gene	24683
33823126	926	942	hemiparkinsonian	Disease	
33823126	943	946	rat	Species	10116
33823126	1029	1033	Rats	Species	10116
33823126	1073	1075	E2	Chemical	MESH:D004958
33823126	1098	1104	L-dopa	Chemical	MESH:D007980
33823126	1213	1216	PRL	Gene	24683
33823126	1221	1223	E2	Chemical	MESH:D004958
33823126	1242	1245	PRL	Gene	24683
33823126	1250	1256	Syt IV	Gene	64440
33823126	1340	1342	E2	Chemical	MESH:D004958
33823126	1384	1390	Syt IV	Gene	64440
33823126	1395	1398	PRL	Gene	24683
33823126	1402	1405	PRL	Gene	24683
33823126	1437	1443	L-dopa	Chemical	MESH:D007980
33823126	1466	1479	prolactinomas	Disease	MESH:D015175
33823126	1498	1504	Syt IV	Gene	64440
33823126	1526	1529	PRL	Gene	24683
33823126	Positive_Correlation	MESH:D004958	24683
33823126	Negative_Correlation	MESH:D007980	MESH:D010300
33823126	Negative_Correlation	MESH:D007980	MESH:D015175
33823126	Negative_Correlation	MESH:D007980	64440
33823126	Positive_Correlation	MESH:D007980	24683
33823126	Association	24683	64440
33823126	Association	MESH:D015175	24683
33823126	Positive_Correlation	MESH:D004958	64440
33823126	Positive_Correlation	MESH:D004958	MESH:D015175

